Status:
RECRUITING
Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Lupus Erythematosus Disseminatus
Autoimmune Diseases
Eligibility:
All Genders
18-80 years
Brief Summary
Systemic lupus erythematosus (SLE) is a severe autoimmune disease in which patients often develop numerous autoantibodies (Abs). Unfortunately, none of the SLE specific Abs described so far (anti-DNA,...
Detailed Description
140 adult patients with lupus and anti-DNA Abs will be prospectively recruited in the University Hospital of Montpellier and Nîmes (department of rheumatology, internal medicine and nephrology) and fo...
Eligibility Criteria
Inclusion
- Patients presenting with LED according to the ACR/EULAR 2019 criteria, all clinical forms combined, quiescent or in flare with positive native anti-DNA antibodies, providing oral informed consent.
Exclusion
- Patients under protection of justice or unable to receive a clear information.
- High probability of non-compliance with the protocol or withdrawal during the study
- Already involved in another interventional clinical study
Key Trial Info
Start Date :
August 23 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 22 2027
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT05394922
Start Date
August 23 2022
End Date
February 22 2027
Last Update
August 5 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Montpellier University Hospital
Montpellier, France
2
Nimes University Hospital
Nîmes, France